158 results
Page 2 of 8
8-K
EX-10.1
rqds1r6
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-1.1
w82a1e9b1cwgg4
14 Feb 24
Other Events
4:11pm
424B5
85e3vo1
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
mzgm98v69paw hxpfr
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
EX-99.2
i8zcg73lpc4 u709i
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.1
qb50ful7a66a4
13 Feb 24
Results of Operations and Financial Condition
4:10pm
S-3ASR
EX-4.4
ayw efho1a000
13 Feb 24
Automatic shelf registration
4:04pm
S-3ASR
EX-4.3
y9is08rn myeh7
13 Feb 24
Automatic shelf registration
4:04pm
S-3ASR
8kdsv1vrvtc9 dg0
13 Feb 24
Automatic shelf registration
4:04pm
8-K
EX-2.1
vtopp0vkktd9m6s lww
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-10.1
nr0cc4 r3stbqtosrc
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
S-8
EX-23.1
s17fucg
2 Feb 24
Registration of securities for employees
4:04pm